

Gordon A Francis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10894797/publications.pdf>

Version: 2024-02-01

61
papers

6,432
citations

117625

34
h-index

133252

59
g-index

61
all docs

61
docs citations

61
times ranked

8129
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	1.7	775
2	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2013, 29, 151-167.	1.7	680
3	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult "2009 recommendations. Canadian Journal of Cardiology, 2009, 25, 567-579.	1.7	653
4	Nuclear Receptors and the Control of Metabolism. Annual Review of Physiology, 2003, 65, 261-311.	13.1	551
5	Contribution of Intimal Smooth Muscle Cells to Cholesterol Accumulation and Macrophage-Like Cells in Human Atherosclerosis. Circulation, 2014, 129, 1551-1559.	1.6	493
6	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	1.7	367
7	Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovascular Research, 2018, 114, 540-550.	3.8	322
8	Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 876-887.	2.4	199
9	The National Niemann-Pick C1 disease database: Report of clinical features and health problems. American Journal of Medical Genetics, Part A, 2007, 143A, 1204-1211.	1.2	158
10	Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovascular Research, 2012, 95, 165-172.	3.8	136
11	Impaired ABCA1-dependent Lipid Efflux and Hypoalphalipoproteinemia in Human Niemann-Pick type C Disease. Journal of Biological Chemistry, 2003, 278, 32569-32577.	3.4	126
12	Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 512-522.	2.8	121
13	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	1.7	105
14	Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism. Frontiers in Cell and Developmental Biology, 2015, 3, 3.	3.7	102
15	ATP-Binding Cassette Transporter A1 Expression and Apolipoprotein A-I Binding Are Impaired in Intima-Type Arterial Smooth Muscle Cells. Circulation, 2009, 119, 3223-3231.	1.6	88
16	The National Niemann-Pick Type C1 Disease Database: correlation of lipid profiles, mutations, and biochemical phenotypes. Journal of Lipid Research, 2010, 51, 406-415.	4.2	84
17	Lysosomal Acid Lipase Deficiency Impairs Regulation of ABCA1 Gene and Formation of High Density Lipoproteins in Cholesteryl Ester Storage Disease. Journal of Biological Chemistry, 2011, 286, 30624-30635.	3.4	79
18	PPAR- δ effects on the heart and other vascular tissues. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1-H9.	3.2	75

#	ARTICLE	IF	CITATIONS
19	PPAR agonists in the treatment of atherosclerosis. <i>Current Opinion in Pharmacology</i> , 2003, 3, 186-191.	3.5	73
20	Niemann-Pick C1 protein regulates cholesterol transport to the trans-Golgi network and plasma membrane caveolae. <i>Journal of Lipid Research</i> , 2002, 43, 579-589.	4.2	71
21	So Much Cholesterol. <i>Current Opinion in Lipidology</i> , 2016, 27, 155-161.	2.7	65
22	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1210-1214.	1.7	62
23	Niemann-Pick C1 protein regulates cholesterol transport to the trans-Golgi network and plasma membrane caveolae. <i>Journal of Lipid Research</i> , 2002, 43, 579-89.	4.2	62
24	Oxidative Tyrosylation of HDL Enhances the Depletion of Cellular Cholesteryl Esters by a Mechanism Independent of Passive Sterol Desorption. <i>Biochemistry</i> , 1996, 35, 15188-15197.	2.5	60
25	The complexity of HDL. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 1286-1293.	2.4	56
26	Peroxisomal proliferator activated receptor- β deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). <i>BMC Medical Genetics</i> , 2006, 7, 3.	2.1	54
27	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2682-2693.	2.8	50
28	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , 2018, 64, 355-362.	3.2	47
29	Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). <i>Canadian Journal of Cardiology</i> , 2010, 26, e330-e335.	1.7	46
30	Pathways of smooth muscle foam cell formation in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2019, 30, 117-124.	2.7	46
31	Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. <i>Journal of Clinical Lipidology</i> , 2015, 9, 741-750.	1.5	42
32	Correction of Apolipoprotein A-I-mediated Lipid Efflux and High Density Lipoprotein Particle Formation in Human Niemann-Pick Type C Disease Fibroblasts. <i>Journal of Biological Chemistry</i> , 2006, 281, 37081-37090.	3.4	39
33	Generation and function of astroglial lipoproteins from Niemann-Pick type C1-deficient mice. <i>Biochemical Journal</i> , 2005, 387, 779-788.	3.7	37
34	The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways. <i>Journal of Molecular Medicine</i> , 2006, 84, 266-275.	3.9	37
35	ABCA1-dependent mobilization of lysosomal cholesterol requires functional Niemann-Pick C2 but not Niemann-Pick C1 protein. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2012, 1821, 396-404.	2.4	37
36	Oxysterol generation and liver X receptor-dependent reverse cholesterol transport: Not all roads lead to Rome. <i>Molecular and Cellular Endocrinology</i> , 2013, 368, 99-107.	3.2	33

#	ARTICLE	IF	CITATIONS
37	The Niemann-Pick C1 gene is downregulated by feedback inhibition of the SREBP pathway in human fibroblasts. <i>Journal of Lipid Research</i> , 2008, 49, 1090-1102.	4.2	31
38	Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. <i>Journal of Lipid Research</i> , 2015, 56, 1993-2001.	4.2	28
39	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. <i>Canadian Journal of Cardiology</i> , 2014, 30, 377-380.	1.7	27
40	Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis. <i>Clinica Chimica Acta</i> , 1999, 286, 219-230.	1.1	25
41	Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation. <i>Current Opinion in Lipidology</i> , 2008, 19, 270-276.	2.7	25
42	Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study. <i>Canadian Journal of Cardiology</i> , 2017, 33, 385-392.	1.7	25
43	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1004-1009.	1.7	24
44	LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1191-1201.	2.4	24
45	Low LAL (Lysosomal Acid Lipase) Expression by Smooth Muscle Cells Relative to Macrophages as a Mechanism for Arterial Foam Cell Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e354-e368.	2.4	23
46	Apolipoprotein AI Efficiently Binds to and Mediates Cholesterol and Phospholipid Efflux from Human but Not Rat Aortic Smooth Muscle Cells. <i>Biochemistry</i> , 1999, 38, 16315-16322.	2.5	22
47	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , 2018, 277, 419-424.	0.8	18
48	High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2020, 14, 459-469.e0.	1.5	18
49	Smooth Muscle Cell-Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	17
50	Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia. <i>Cmaj</i> , 2005, 172, 495-497.	2.0	16
51	Nonfasting lipid testing: the new standard for cardiovascular risk assessment. <i>Cmaj</i> , 2018, 190, E1317-E1318.	2.0	15
52	Cholesterol and phospholipid efflux from cultured cells. <i>Methods</i> , 2005, 36, 196-206.	3.8	12
53	The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. <i>Clinical Cardiology</i> , 2018, 41, 888-895.	1.8	11
54	Physiological and coordinate downregulation of the NPC1 and NPC2 genes are associated with the sequestration of LDL-derived cholesterol within endocytic compartments. <i>Journal of Cellular Biochemistry</i> , 2009, 108, 1102-1116.	2.6	10

#	ARTICLE	IF	CITATIONS
55	Multiplexed LC-ESI-MRM-MS-based Assay for Identification of Coronary Artery Disease Biomarkers in Human Plasma. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1700111.	1.6	8
56	Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	7
57	Colesevelam as an Add-On Treatment for Control of Dyslipidemia and Hyperglycemia in Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2016, 40, 112-114.	0.8	5
58	Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100036.	3.0	4
59	Response to Letter Regarding Article, "Contribution of Intimal Smooth Muscle Cells to Cholesterol Accumulation and Macrophage-Like Cells in Human Atherosclerosis". <i>Circulation</i> , 2015, 131, e25.	1.6	3
60	Autophagy in Atherosclerosis: Not All Foam Cells Are Created Equal. <i>Circulation Research</i> , 2022, 130, 848-850.	4.5	3
61	Low Rates of Identification and Treatment of Familial Hypercholesterolemia in France and Elsewhere: A Call for Universal Screening. <i>Canadian Journal of Cardiology</i> , 2019, 35, 699-700.	1.7	0